Makena Capital Management’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3,149,554
Closed -$24.1M 43
2023
Q3
$24.1M Buy
3,149,554
+2,500,000
+385% +$18.8M 5.16% 1
2023
Q2
$4.68M Hold
649,554
0.89% 41
2023
Q1
$3.96M Hold
649,554
0.75% 41
2022
Q4
$2.83M Hold
649,554
0.53% 41
2022
Q3
$2.55M Hold
649,554
0.42% 45
2022
Q2
$3.31M Hold
649,554
0.54% 44
2022
Q1
$4.16M Hold
649,554
0.5% 43
2021
Q4
$5.21M Buy
+649,554
New +$6.12M 0.59% 42

Other funds holding CLBT

Makena Capital Management's CLBT Position: Q4 2023 in Review

Makena Capital Management sold out of Cellebrite (CLBT) in Q4 2023, closing a stake of 3,149,554 shares — an estimated $24.1M sold.

Makena Capital Management first reported a position in CLBT in Q4 2021 and held it in 8 quarters. The position peaked at $24.1M in Q3 2023. 116 funds tracked by Wall St. Rank hold CLBT as of Q4 2023.

  • Makena Capital Management reported no remaining Cellebrite position as of Q4 2023 after selling out during the quarter.
  • Makena Capital Management sold 3,149,554 Cellebrite shares in Q4 2023, an estimated $24.1M.
  • Makena Capital Management first reported a position in Cellebrite in Q4 2021 and held it in 8 quarters.
  • Makena Capital Management's Cellebrite position peaked at $24.1M in Q3 2023.
  • 116 funds tracked by Wall St. Rank held Cellebrite as of Q4 2023.

Based on Makena Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.